Screener
CG Oncology CGON Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $1.16M— | $1.08M+1,983% | $2.32M+409% | $1.67M+3,774% | $0-100% | ||
| $54.66M+74.5% | $43.73M+59.2% | $29.96M+11.8% | $27.88M+42.1% | $31.33M+69.6% | ||
| $28.98M+66.4% | $20.78M+40.5% | $17.99M+53.7% | $23.33M+168% | $17.41M+132% | ||
| $87.56M+79.6% | $67.47M+59.7% | $51.02M+32.5% | $52.8M+86.3% | $48.74M— | ||
| -$86.4M-77.3% | -$66.39M-57.3% | -$48.7M-28.0% | -$51.13M-80.7% | -$48.74M-88.5% | ||
| -7,467.7%— | -6,130.1%+75,031pp | -2,097.3%+6,247pp | -3,069%+62,733pp | —— | ||
| $7.35M+0.4% | $6.19M-20.2% | $7.39M+18.2% | $7.32M-7.2% | $7.32M+5.2% | ||
| -$79.06M-90.8% | -$60.2M-74.7% | -$41.31M-29.9% | -$43.81M-115% | -$41.43M-119% | ||
| -6,832.8%— | -5,558.8%+60,695pp | -1,779%+5,194pp | -2,629.5%+44,824pp | —— | ||
| -$0.90-66.7% | -$0.71-57.8% | -$0.51-6.3% | -$0.57-90.0% | -$0.54-92.9% | ||
| -$85.55M-76.1% | -$65.55M-55.4% | -$47.85M-25.8% | -$50.71M-79.4% | -$48.59M-88.0% | ||
| -7,394.2%— | -6,052.4%+75,063pp | -2,060.8%+6,283pp | -3,044%+62,709pp | —— | ||
| -$86.4M-77.3% | -$66.39M-57.3% | -$48.7M-28.0% | -$51.13M-80.7% | -$48.74M-88.5% |
FAQ
- What is CG Oncology's revenue?
- CG Oncology (CGON) generated $6.2M in revenue over the trailing twelve months, up 1030.3% year over year.
- Is CG Oncology profitable?
- CG Oncology is not currently profitable: it reported a net loss of $224.4M over the trailing twelve months, a -3602.7% net margin.
- What is CG Oncology's earnings per share?
- CG Oncology's diluted EPS over the trailing twelve months is $-2.69.
- Where does CG Oncology's income statement data come from?
- Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
